Arcturus Therapeutics Enhances Board with Industry Expert Dr. Slaoui

Arcturus Therapeutics (ARCT) has shared an announcement.

Arcturus Therapeutics Holdings Inc. has appointed Dr. Moncef Slaoui to its Board of Directors, bringing on board a seasoned veteran with extensive experience in the vaccine industry and biotechnology sector. Dr. Slaoui, who has previously held significant roles at GlaxoSmithKline and served as chief advisor to Operation Warp Speed, is expected to contribute valuable operational and strategic insights to the company. His tenure will last until the next annual meeting of stockholders, and his compensation aligns with that of other non-employee board members.

See more data about ARCT stock on TipRanks’ Stock Analysis page.